Screening
Figure 25: Nanion’s SyncroPatch 96 ion channel screening platform records from 96 cells in parallel
2006, offering full automation of patch clamp recordings from eight cells in parallel. Both plat- forms support versatile functions such as tempera- ture control, current clamp recordings, fast perfu- sion and automated internal solution exchange. The Patchliner has shown great compatibility with primary cells, as described in high rank journals such as Nature and Nature Protocols7,8. Currently, the Patchliner receives much attention because of the possibilities to run automated current clamp recordings, for example for investigating com- pound effects on action potentials from cardiac cells. Nanion’s screening flagship, the SyncroPatch 96, was launched in the beginning of 2010 and was quickly adopted by the pharmaceutical industry. Like all other Nanion products, the SyncroPatch 96 supports giga-seal recordings, however with a drastically increased throughput: up to 9,000 data points can be collected per day. The SyncroPatch 96 records from 96 cells is parallel and has been validated with both voltage- and advanced ligand- gated ion channels such as nicotinic acetyl choline receptors (7) and TRPA1. Set-up and running the
Task defines tool – why drug discovery has an advantage over rocket science Rocket science basics:
• How far do you want to get? • Build a powerful, lightning fast rocket that fits your task
• Discover! Drug discovery basics:
• How far do you want to get? • The SyncroPatch®
96 is made for your mission – just use it • Discover!
Supercharge your ion channel drug discovery project: the SyncroPatch®
96 is the most powerful, lightning fast automated patch clamp platform you can get on this planet.
60
Drug Discovery World Fall 2011
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92